<SEC-DOCUMENT>0001372514-25-000003.txt : 20250115
<SEC-HEADER>0001372514-25-000003.hdr.sgml : 20250115
<ACCEPTANCE-DATETIME>20250115172254
ACCESSION NUMBER:		0001372514-25-000003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250115
DATE AS OF CHANGE:		20250115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		25533748

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20250110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b95297b3-4120-4902-a1ed-c91851d8eedf,g:f30a331b-4605-4c84-a3e8-7fcd5123b499,d:8d8d6b3495e445118d4d0c8972a53d13-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20250110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20250110.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8d8d6b3495e445118d4d0c8972a53d13_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 10, 2025</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-20">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8d8d6b3495e445118d4d0c8972a53d13_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daniels Employment Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 10, 2025, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an employment agreement (the &#8220;Daniels Agreement&#8221;) with Eric Daniels, MD, MBA, the Company&#8217;s Chief Development Officer, in connection with the relocation of Dr. Daniels from Australia to the United States. Pursuant to the Daniels Agreement, Dr. Daniels will receive an annual base salary of&#8201; $443,000.04 and he is entitled to receive a performance bonus with a target of up to 40% of his annual base salary for the applicable fiscal year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for a period of fifteen months from the effective date of the Daniels Agreement, the Company granted Dr. Daniels certain relocation benefits, including certain tax gross-up payments and relocation expenses. The Company will also continue to make concessional superannuation contributions (capped at AUD$30,000 annually) as previously provided to Dr. Daniels through  the Company&#8217;s Australian subsidiary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Dr. Daniels voluntarily terminates employment with the Company, or is terminated for Cause (as defined in the Daniels Agreement) within twelve months of the effective date of the Employment Agreement, Dr. Daniels will be required to reimburse the Company for 50% of all previously reimbursed relocation expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company terminates Dr. Daniels&#8217; employment without Cause or he resigns for Good Reason (as such terms are defined in the Daniels Agreement), then Dr. Daniels will be eligible to receive (i) continued payment of his base salary for six months; (ii) a lump-sum cash payment, payable no later than the last installment of his severance, equal to 0.5 multiplied by the maximum performance bonus that he would have been eligible to receive in the year of termination; and (iii) continued coverage under a private health and dental insurance plan for up to six months following termination.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the Company terminates Dr. Daniels&#8217; employment without Cause or he resigns for Good Reason, then that portion of his then unvested stock options and restricted stock awards that would have otherwise become vested over the six month period following such termination will become fully vested and immediately exercisable on the date of such termination. In the event that a Change of Control of the Company occurs (as such term is defined in the Daniels Agreement), all of Dr. Daniels&#8217; unvested stock options and restricted stock awards will become fully vested and immediately exercisable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Daniels Agreement is a summary and does not purport to be complete. Such description is qualified in its entirety by reference to the text of the Daniels Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tosca Employment Agreement</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the previous promotion of Melissa Tosca to Chief Financial Officer on July 1, 2024, the Company entered into an Employment Agreement (the &#8220;Tosca Agreement&#8221;) with Ms. Tosca on January 10, 2025. Pursuant to the Tosca Agreement, Ms. Tosca will receive an annual base salary of&#8201; $337,000 and she is entitled to receive a performance bonus with a target of up to 40% of her annual base salary for the applicable fiscal year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company terminates Ms. Tosca&#8217;s employment without Cause or she resigns for Good Reason (as such terms are defined in the Tosca Agreement), then Ms. Tosca will be eligible to receive (i) continued payment of base salary for six months; and (ii) a lump-sum cash payment, payable no later than the last installment of her severance, equal to 0.5 multiplied by the maximum performance bonus that she would have been eligible to receive in the year of termination; and (iii) continued coverage under a private health and dental insurance plan for up to six months following termination.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the Company terminates Ms. Tosca&#8217;s employment without Cause or she resigns for Good Reason, then that portion of her then unvested stock options and restricted stock awards that would have otherwise become vested over the six month period following such termination shall become fully vested and immediately exercisable on the date of such termination. In the event that a Change of Control of the Company </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">occurs (as such term is defined in the Tosca Agreement), all of Ms. Tosca&#8217;s unvested stock options and restricted stock awards shall become fully vested and immediately exercisable.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Tosca Agreement is a summary and does not purport to be complete. Such description is qualified in its entirety by reference to the text of the Tosca Agreement, which is filed as Exhibit 10.2 to this Current Report on Form 8-K, and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div id="i8d8d6b3495e445118d4d0c8972a53d13_16"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit-101.htm">10.1</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="exhibit-101.htm">1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">Employment Agreement by and between Kiora Pharmaceuticals</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">, Inc. and Eric J. Daniels, date</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">d as of January </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">, 2025</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit-102.htm">10.2</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">Employment Agreement by and between Kiora Pharmaceuticals, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">Melissa Tosca</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">, dated as of January </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-102.htm">, 2025</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contract or compensatory plan or arrangement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i8d8d6b3495e445118d4d0c8972a53d13_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.841%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: January 15, 2025</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit-101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id3b9eaacd16c4fe8832e8c6623d8e083_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">KIORA PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">THIS EMPLOYMENT AGREEMENT, entered into as of January 10, 2025 (this &#8220;Agreement&#8221;), is made by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Employer&#8221;), and Eric J. Daniels, MD, MBA (the &#8220;Employee&#8221;) (Employer and Employee collectively, the &#8220;Parties&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">WHEREAS, the Employer desires to employ the Employee and the Employee desires to be employed by the Employer, upon and subject to the terms set forth in this Agreement&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NOW, THEREFORE, in consideration of the covenants and the mutual promises contained herein, the Parties hereto hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Freedom to Contract</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  The Employee represents that he is free to enter into this Agreement, that he has not made and will not make any agreements in conflict with this Agreement, and that he will not disclose to the Employer, or use for the Employer&#8217;s benefit, any trade secrets or confidential information that are the property of any other party.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer hereby employs the Employee, and the Employee hereby accepts his employment by the Employer, subject to and upon the terms and conditions set forth herein. The Employee shall be an &#8220;at-will&#8221; employee, subject to the terms and provisions of this Agreement. This means that Employee&#8217;s employment is of no definite duration and will continue only as long as both Parties consider it of mutual benefit. Notwithstanding Section 10.2 or any other provision of this Agreement, Employee or Employer are free to terminate the employment relationship at any time with or without cause and with or without notice. Although Employee&#8217;s job duties, title, compensation and benefits, as well as Employer&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Employee&#8217;s employment may only be changed in a document signed by Employee and Employer&#8217;s Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Effective Date and Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The effective time of this Agreement shall be as of January 1, 2025 (the &#8220;Effective Date&#8221;) and such employment shall continue thereafter in full force and effect until terminated by either Party in accordance with the provisions of this Agreement. The obligations and agreements of the Employee pursuant to Sections 8.7, 10.2, 10.3, 11, 12, 13, and 15.6 hereof shall survive the termination of this Agreement for any reason. The Enterprise Effective Date (the &#8220;Start Date&#8221;) is October 21, 2021.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Title and Duties&#59; Extent of Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt">The Employee shall promote the business and affairs of the Employer as Chief Development Officer. As Chief Development Officer of the Employer, the Employee shall have such duties and responsibilities as may be assigned to him by the Employer&#8217;s President and Chief Executive Officer and its Board of Directors (the &#8220;Board of Directors&#8221;) from time to time and such other duties and responsibilities as are normal and customary for Chief Development Officers. The Employee shall report and be responsible to the Chief Executive Officer. The Employee shall devote his best efforts and entire time, attention and energies to the business and affairs of the Employer. Subject to Section 4.2, unless the Employee has received the approval of the Chief Executive Officer, he shall not participate in any other business, engage in other business activities, or render services to any other business or person, as a principal, consultant, employee, or in any other capacity.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt">During his employment, the Employee may serve on the board of directors, board of advisors, or other similar governing or advisory boards of other companies, institutions, or organizations with the prior written consent of the Chief Executive Officer (not to be unreasonably withheld), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that&#58; (i) the Employee does not use proprietary, confidential and&#47;or trade secret information, property, assets or employees of the Employer in engaging in such activities&#59; (ii) any such activities do not pose a conflict of interest or interfere with the Employee&#8217;s duties to the Employer&#59; and (iii) any such activities are not directly or indirectly for or for the benefit of a business engaged in any commercial activity that is competitive with the Employer or otherwise in breach of the Confidentiality Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:9.67pt">&#91;Reserved&#93;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Compliance with Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Employee acknowledges and agrees that compliance with Employer&#8217;s policies, practices, and procedures is a term and condition of his employment under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Location of Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Employee shall work out of Employee&#8217;s home office in San Diego County or shall work at any other location mutually agreed upon by the Employer and the Employee, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that Employee complies with his obligations to travel regularly for business from time to time, consistent with the Employer&#8217;s business needs.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer shall pay the Employee a gross salary at the rate of Thirty-Six Thousand, Nine Hundred and Sixteen Dollars and Sixty-Seven Cents ($36,916.67) per month (which annualizes to Four Hundred, Forty-Three Thousand Dollars and Four Cents ($443,000.04)), subject to all applicable statutory deductions and withholdings, and payable bi-weekly in arrears or otherwise in accordance with state and local law as well as the Employer&#8217;s normal and customary payroll practices applicable to all of its employees (&#8220;Salary&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  The Employee shall be eligible to receive a performance bonus with respect to each fiscal year of the Employer. Payment of any such performance bonus and the amount, if any, of any such performance bonus shall be entirely at the discretion of the Board of Directors, with an annual target of up to forty percent (40%) of the Employee&#8217;s annual Salary (&#8220;Performance Bonus&#8221;). In determining the amount of any Performance Bonus to be paid to Employee, the Board of Directors shall consider the extent to which the performance criteria established between the Employee and the Board of Directors with respect to such fiscal year has been achieved. Notwithstanding anything express or implied in this Section 8.2 to the contrary, in order to be entitled to receive any performance bonus, the Employee must remain an employee of the Employer on the date that the Employer makes payment of any Performance Bonus.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Medical Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  During the term of this Agreement, the Employee shall be entitled to participate in the health insurance plan offered or generally made available to the Employer&#8217;s employees, under the same terms and conditions as those offered to other, similarly situated employees of the Employer, except as otherwise provided in Section 10.2(d) hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Paid Time Off and Choice Leave</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  During the term of this Agreement, the Employee shall be entitled to paid time off and choice leave, which includes paid sick leave, consistent with the Employer&#8217;s policy concerning paid time off and choice leave and applicable state and local law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. During the term of the Employee&#8217;s employment with the Employer pursuant to this Agreement, the Employee shall be entitled to receive such other retirement, welfare and fringe benefits (&#8220;employee benefits&#8221;) as are provided by the Employer to its senior executives and&#47;or key employees, in each case in accordance with the terms and conditions set forth in the plan, agreement or arrangement representing or evidencing such benefits.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.5.1   For the term of fifteen (15) months from the Effective Date of this Agreement, unless otherwise specified below, the Employee will receive the following &#8220;Other Benefits&#8221;. At the end of this term, these will be reevaluated&#58; </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.67pt">Supplemental Gross Up. The Employer shall pay the Employee a supplemental gross up, including all applicable federal, state, and local deductions, in the amount of Six Thousand Five Hundred Dollars ($6,500) per month. </font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.67pt">Medical Benefits. In addition to Medical Benefits in Section 8.3, the Employer will continue to provide private family health insurance as currently provided to the Employee through the Employer&#8217;s wholly owned Australian subsidiary (Kiora Pharmaceuticals, Pty Ltd.). </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.23pt">Superannuation Contribution. The Employer shall continue to make concessional Superannuation contributions (capped at AUD$30,000 annually) as currently provided to the Employee through the Employer&#8217;s wholly owned Australian subsidiary (Kiora Pharmaceuticals, Pty Ltd.). </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.67pt">California Tax Equalization. For tax years 2025 and 2026, the Employer agrees to reimburse or pay the Employee directly (including all applicable federal, state, and local tax) up to Thirty Thousand Dollars (USD$30,000) in the event that tax due in California exceeds a hypothetical tax return to be run in Melbourne, Victoria (&#8220;stay-at-home tax&#8221;) for the identical 12-month period. </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.67pt">Reimbursed Relocation Expenses. The Employer will reimburse the Employee for relocation expenses up to Fifty Thousand Dollars (USD$50,000). If the Employee voluntarily terminates employment with the Employer, or is terminated for Cause (defined below in Section 10.2(b)), within twelve (12) months of the Effective Date, the Employee will be liable to reimburse Employer for 50% of all incurred relocation expenses reimbursed and paid by Employer through the date of termination. Employee agrees to execute any necessary reimbursement agreements to effectuate this Section 8.5.1(e). </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Discretionary Nature of Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Except as outlined in Section 8.5.1, the Employee understands that the Employer may amend, change or cancel or terminate any of its employment policies and &#8220;employee benefits&#8221; at any time as allowed by law or by any applicable plan, agreement or arrangement representing or evidencing such employee benefits.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Except for the payments and benefits listed in Section 8.5.1, all compensation and benefits (including, without limitation, any fringe benefits, bonuses, non-cash compensation, subsidies, severance pay or benefits under Article 8 and Section 10.2 hereof) payable or to be provided to the Employee shall be subject to all applicable withholding taxes, to applicable foreign, federal, state and local deductions, and to any other proper deductions.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Stock Options&#59; Acceleration Upon Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt">The Employee shall be eligible for grants of stock options (the &#8220;Options&#8221;) under the Employer&#8217;s 2024 Equity Incentive Plan, as may be amended from time to time (the &#8220;Plan&#8221;), subject to the discretion of the Board of Directors. The Options shall be incentive stock options to purchase shares of the Employer&#8217;s common stock, $0.01 par value per share (the &#8220;Common Stock&#8221;). The Options, if any, shall be subject to, and governed by, the terms and provisions of the Plan and stock option agreement(s) granted thereunder (&#8220;Stock Option Agreements&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:1.34pt">Upon a Change of Control, all of the Employee&#8217;s then unvested stock options and&#47;or restricted stock awards granted to the Employee prior to such Change of Control under the Plan, including, but not limited to, all stock options previously granted, shall become fully vested and immediately exercisable, notwithstanding any vesting schedule or other provisions to the contrary in the agreements evidencing such options or awards, and the Employer and the Employee hereby agree that such stock option agreements and restricted stock awards are hereby, and will be deemed to be, amended to give effect to this provision. For the purposes hereof, a &#8220;Change of Control&#8221; occurs upon (a) the closing of any merger or consolidation of the Employer with any other unrelated person or entity, or (b) the sale of all or substantially all of the assets of the Employer to another unrelated person or entity, or (c) the sale of more than fifty percent (50%) of the total voting power </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">of the stock of the Employer to an unrelated party, such that, in each case, the transaction has been approved by the Employer&#8217;s stockholders, and in which the stockholders of the Employer immediately prior to such merger, consolidation or sale shall, immediately after such merger, consolidation or sale, own less than fifty percent (50%) of the issued and outstanding capital stock of the person or entity that is the surviving company of any such merger or consolidation, or the acquirer in the case of any such sale of all or substantially all of the assets of the Employer. The provisions of this paragraph shall apply only if the Employee is actively employed by the Employer as a full time employee at the time of a Change of Control.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:0.28pt;text-decoration:underline">Termination Rights of the Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer may terminate the Employee&#8217;s employment at any time by giving notice of termination to the Employee, whereupon, unless otherwise specified by the Employer, the date of termination of the Employee&#8217;s employment shall be the date on which notice of termination is given to the Employee. Upon the death of the Employee or the Employee&#8217;s disability such that he is unable to perform his duties as determined, in good faith, by the Chief Executive Officer, his employment shall terminate immediately upon such occurrence. Subject to Section 13, the date on which the Employee&#8217;s employment terminates hereunder is hereinafter referred to as the &#8220;Termination Date&#8221;.</font></div><div style="padding-left:36pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:0.28pt;text-decoration:underline">Employee&#8217;s Right to Compensation Following Termination&#59; Severance Pay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If the Employee&#8217;s employment hereunder terminates for any reason whatsoever, the Employer shall pay all of his (or, in the case of death, his estate) accrued but unpaid Salary and Paid Time Off through and including the Termination Date, which amounts shall be paid to the Employee (or his estate) in a lump sum as of such Termination Date, in accordance with applicable law. Subject to the terms and conditions of this Agreement, the Employee shall also be entitled to such other accrued benefits for which he is eligible under the terms and conditions of the Employer&#8217;s employee benefit plans, stock options arrangements, and any applicable law. The accrued compensation and benefits described in this Section 10.2(a) are collectively referred to as the &#8220;Accrued Benefits.&#8221;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If (i) the Employee voluntarily terminates his employment hereunder without Good Reason (as defined in Section 10.2(e) below) or (ii) the Employee&#8217;s employment hereunder terminates by reason of his death or disability or (iii) the Employer terminates the employment of the Employee, at any time, for Cause, then, other than the Accrued Benefits, neither the Employee nor his estate, heirs or other successors shall be entitled to severance pay or other benefits under this Agreement after the Termination Date.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt">If the employment of the Employee is terminated by the Employer for any reason other than for Cause (as defined in Section 10.2(e) below) at any time or if the employment of the Employee is terminated by the Employee for Good Reason then, subject to Sections 10.3 and 13 and subsection (d) hereof, and in addition to the Accrued Benefits, the Employee shall be entitled to&#58; (i) severance pay in the form of a continuation of the periodic payment of his Salary for a period of six (6) months from the Termination Date&#59; and (ii) an amount equal to the product of (A) the maximum performance bonus, pursuant to Section 8.2, that he would have been eligible to receive for the year in which such termination occurs, multiplied by (B) 0.5, which shall be payable no later than the last installment of his severance. The continued Salary payments referred to in the foregoing clause (i) shall be made in accordance with the Employer&#8217;s standard payroll practices and timing as in effect from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If (i) the employment of the Employee is terminated by the Employer for any reason other than for Cause, or if the employment of the Employee is terminated by the Employee for Good Reason at any time, and (ii) if the Employee elects under COBRA or an analogous state law continuation coverage under the Employer&#8217;s health and dental plans, then the Employer will subsidize the cost of such coverage and pay the employer portion of such coverage for a period of six (6) months from the Termination Date, under the same terms and conditions then applicable to active employees with identical coverage (&#8220;COBRA Subsidy&#8221;), except that the Employee must pay the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">employee portion for such coverage by making each monthly co-payment to the Employer, in full, no later than the first five (5) business days of any month during which such COBRA Subsidy applies. If the Employee has elected continuation coverage under COBRA or any analogous state law, then the Employee shall be responsible for all costs for any remainder of the COBRA (or analogous) period. If the Employee has, instead, elected health and dental coverage under a state exchange, then the Employee shall pay the cost of premiums for such coverage directly, subject to reimbursement by the Employer for an amount equal to the COBRA Subsidy, and the Employer shall pay any such reimbursement, in full, no later than thirty (30) days after the eighteen (18) month anniversary of the Employee&#8217;s Termination Date. Notwithstanding anything herein to the contrary, (A) the amount of the COBRA Subsidy shall not exceed the dollar amount provided to similarly situated active employees of the Employer, and (B) to the extent that the Employer&#8217;s payment of such COBRA Subsidy to the Employee is treated as a violation of any applicable non-discrimination laws under the Affordable Care Act, then such COBRA Subsidy shall be unavailable to the Employee under this subsection and his severance under subsection (c) hereof shall be increased by an amount equal to the dollar value of the COBRA Subsidy that would have otherwise been available. Notwithstanding any other provision herein to the contrary, any reimbursement of the COBRA Subsidy shall be paid to the Employee no later than December 31 of the year following the year in which the COBRA expense was incurred.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">For purposes of this Agreement, &#8220;Cause&#8221; shall mean (i) the Employee&#8217;s willful failure to perform his duties (other than any such failure resulting from incapacity due to physical or mental illness or any protected reason under federal, state, or local law), (ii) the Employee&#8217;s willful failure to comply with any valid directive of the Board of Directors, (iii) the Employee&#8217;s engagement in dishonesty, illegal conduct, or misconduct, which is, in each case, materially injurious to the Employer or its affiliates, (iv) the Employee&#8217;s embezzlement, misappropriation, or fraud, whether or not related to the Employee&#8217;s employment with the Employer, (v) the Employee&#8217;s conviction or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude, subject to applicable law, (vi) the Employee&#8217;s material violation of the Employer&#8217;s written policies or codes of conduct, or (vii) the Employee&#8217;s material breach of any material obligation under this Agreement, the Confidentiality Agreement or any other written agreement between the Employee and the Employer. For the purposes of this Agreement, &#8220;Good Reason&#8221; shall mean (i) the failure of the Employer to employ the Employee in his current position such that Employee&#8217;s duties, authority, or responsibilities are materially diminished without the Employee&#8217;s consent&#59; (ii) a material reduction in the Employee&#8217;s aggregate Salary below the amount stipulated in Section 8.1 hereof without the Employee&#8217;s consent (unless such reduction is in connection with a proportional reduction in compensation to all or substantially all of the Employer&#8217;s officers)&#59; or (iii) a material breach by the Employer of this Agreement. The Employee cannot terminate employment for Good Reason unless the Employee has provided written notice to the Employer of the existence of the circumstances providing grounds for termination for Good Reason and the Employer has had at least thirty (30) calendar days from the date on which such notice is provided to cure such circumstances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:8.57pt">In the event that the employment of the Employee is terminated by the Employer for any reason other than for Cause or in the event that the Employee voluntarily terminates his employment hereunder for Good Reason, then that portion of the Employee&#8217;s then unvested stock options and&#47;or restricted stock awards granted to the Employee under any Employer stock option plan which would have become vested over the three (3) month period following such termination (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that such period shall be extended to a total of six (6) months if the Employee&#8217;s date of termination occurs on or after the eighteen (18) month anniversary of the Start Date or at any time following a Change of Control) had the Employee continued as an employee of Employer throughout such applicable period, shall, instead, become fully vested and immediately exercisable on the Termination Date, notwithstanding any vesting schedule or other provisions to the contrary in the agreements evidencing such options or awards, and the Employer and the Employee hereby agree that such stock option agreements and restricted stock awards are hereby, and will be deemed to be, amended to give effect to this provision.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">The Employee hereby acknowledges and agrees that (i) he shall not be entitled to receive any compensation or benefits from the Employer with respect to any period of time after the Termination Date except to the extent any Accrued Benefits and as otherwise expressly provided in this Section 10.2.&#59; and (ii) the Employer may set off any amounts the Employee owes the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Employer against any amounts the Employer owes the Employee at the date of termination except for amounts the Employer is not entitled by law to set off. Employee agrees to execute any agreement outlining and agreeing to such an offset.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.3  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Employee Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  Any obligation of the Employer to provide the Employee severance payments or other benefits under this Agreement is expressly conditioned upon the Employee reviewing and signing (and not revoking during any applicable revocation period) a general release of claims in a form reasonably satisfactory to the Employer and to the Employee (the &#8220;Release&#8221;). The Employer shall provide the Employee with the Release promptly after the date on which the Employee gives or receives, as the case may be, notice of termination of the Employee&#8217;s employment. Payment of all severance payment or other benefits to which the Employee may be entitled after the Termination Date, other than the Accrued Benefits, shall commence after the effective date of the Release, as set forth in the Release. To the extent that the Release&#8217;s effective date occurs after severance payments or other benefits may become due under Section 10.2 hereof, the payments that have accumulated between the Termination Date and before the Release&#8217;s effective date will be paid in a lump sum in the first payment made after the Release&#8217;s effective date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Proprietary Information, Inventions and Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employee hereby acknowledges that he has entered into the Employer&#8217;s standard form of Proprietary Information, Inventions and Non-Solicitation Agreement (the &#8220;Confidentiality Agreement&#8221;), which is incorporated herein as if reproduced in its entirety. By accepting this Agreement, the Employee hereby ratifies and accepts the terms of the Employee Proprietary Information, Inventions and Non-Solicitation Agreement and agrees to abide by its terms. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">12. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Unique Nature of Agreement&#59; Specific Enforcement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer and the Employee agree and acknowledge that the rights and obligations set forth with this Agreement are of a unique and special nature and that the Employer is, therefore, without an adequate legal remedy in the event of the Employee&#8217;s violation of any of the covenants set forth in this Agreement. The Employer and the Employee agree, therefore, that each of the covenants made by the Employee under this Agreement shall be specifically enforceable in equity, without the need to post a bond or provide other security, in addition to all other rights and remedies, at law or in equity or otherwise (including termination of employment), that may be available to the Employer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Section 409A of the Code.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Anything in this Agreement to the contrary notwithstanding, if at the time of the Employee&#8217;s separation from service within the meaning of Section 409A of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the Employer determines that the Employee is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then the payment of any deferred compensation hereunder shall not commence until the date that is the earlier of&#58; (A) six (6) months and one (1) calendar day after the Employee&#8217;s separation from service&#59; and (B) his death. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Any installment payments of severance or other deferred compensation under this Agreement shall be deemed a series of separate payments for purposes of section 409A of the Code.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">To the extent necessary to comply with Section 409A of the Code, if the period for considering and executing the Release under this Agreement spans two (2) calendar years, then the severance or payment will not be made or commence until the later calendar year.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Notwithstanding anything herein to the contrary, no event shall constitute a &#8220;termination of employment&#8221; in this Agreement, unless such event is also a &#8220;separation from service,&#8221; as that term is defined for purposes of Section 409A of the Code and Treasury Regulations &#167;1.409A-3(a)(1) and 1.409A-1(h), and any references hereunder to &#8220;termination of employment&#8221; shall have the same meaning as &#8220;separation from service,&#8221; as so defined.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">The Parties intend that this Agreement will be administered in accordance with Section 409A of the Code such that no tax is triggered thereunder. To the extent that any provision of this Agreement is ambiguous as to such compliance with Section 409A of the Code, the provision shall be read in such a manner that all payments hereunder so comply with Section 409A of the Code. The Parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional tax cost to either party.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">The Employer makes no representation or warranty as to the compliance of this Agreement with Code Section 409A, and, other than its tax withholding obligation, the Employer shall have no liability to the Employee or any other person if any provisions of this Agreement is determined to constitute deferred compensation taxable under Section 409A of the Code. However, the Parties agree to reasonably cooperate and work together to adopt amendments to this Agreement to the extent necessary to comply with Section 409A of the Code with the intent to avoid liability under Code Section 409A.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Treatment of Parachute Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:31.78pt">Notwithstanding any other provision of this Agreement to the contrary, if any of the payments or benefits provided or to be provided by the Employer or its affiliates to the Employee or for the Employee&#8217;s benefit pursuant to the terms of this Agreement or otherwise (&#8220;Covered Payments&#8221;) constitute parachute payments (&#8220;Parachute Payments&#8221;) within the meaning of Section 280G of the Code and would, but for this Section 14, be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the &#8220;Excise Tax&#8221;), then, subject to Section 14.3, the Covered Payments shall be either&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#8220;Reduced Amount&#8221;)&#59; or</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">payable in full if the Employee&#8217;s receipt on an after-tax basis of the full amount of payments and benefits (after taking into account the applicable federal, state, local and foreign income, employment and excise taxes (including the Excise Tax)) would result in the Employee receiving an amount at least five percent (5%) greater than the Reduced Amount.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.2  Any such reduction pursuant to Section 14.1 shall be made in accordance with Section 409A of the Code and the following&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">the Covered Payments which do not constitute nonqualified deferred compensation subject to Section 409A of the Code shall be reduced first&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">all other Covered Payments shall then be reduced as follows&#58; (i) cash payments shall be reduced before non-cash payments&#59; and (ii) payments to be made on a later payment date shall be reduced before payments to be made on an earlier payment date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.3  Any determination required under this Section 14, including whether any payments or benefits are Parachute Payments, shall be made by the Employer in its reasonable discretion. The Employee shall provide the Employer with such information and documents as the Employer may reasonably request in order to make a determination under this Section 14. The Employer&#8217;s determination shall be final and binding on the Employee.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Equal Employment Opportunity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer is an equal opportunity employer and is committed to providing a work environment that is free of discrimination. In keeping with this commitment, we maintain a strict policy prohibiting unlawful discrimination based on race (including traits typically associated with race such as certain hairstyles), color, creed, religion (includes religious dress and grooming practices), sex, gender (including pregnancy, childbirth, breastfeeding and&#47;or related medical conditions), reproductive health decisions, gender identity and&#47;or gender expression (including, without limitation, transgender, transsexualism, non-binary, gender non-conforming), marital status, sexual orientation, age (40 and over), national origin (including language use and possession of a driver&#8217;s license issued to persons unable to prove their presence in the United States as authorized under federal law), citizenship, immigration status, military or veteran status, physical handicap, disability (physical and mental, including HIV and AIDS), medical condition, genetic characteristic or information, ancestry, the use of cannabis off the job and away from the workplace, or based on any other consideration made unlawful by federal, state, or local laws. This commitment applies to all personnel decisions and to all persons involved  in  our  operations,  including  volunteers  and  interns.  The  Employer  prohibits discrimination not just on the basis of individual protected characteristics, but also on the basis of the intersectionality (combination) of two or more protected traits. Employee is expressly prohibited from discriminating against, retaliating against, or harassing any employee, customer, contractor, or intern of the Employer. Employee must treat all individuals working for or on behalf of the Employer respectfully and appropriately.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement, the Confidentiality Agreement, and the Stock Option Agreements shall represent the entire agreement of the Parties with respect to the arrangements contemplated hereby. No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this Agreement. This Agreement may be amended only by a written instrument executed in one or more counterparts by the Parties.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder. Failure on the part of either Party to complain of any act or failure to act of the other Party or to declare the other Party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver hereunder shall be effective unless it is in writing, executed by the Party waiving the breach or default hereunder.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their respective successors and assigns and, in the case of the Employee, his heirs. This Agreement may be assigned by the Employer to any Affiliate of the Employer and to a successor of its business (whether by purchase or otherwise). &#8220;Affiliate of the Employer&#8221; means any person which, directly or indirectly, controls or is controlled by, or is under common control with, the Employer and, for the purposes of this definition, &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of another, whether through the ownership of voting securities, the holding of office in another, by contract, or otherwise. The Employee may not assign or transfer any or all of his rights or obligations under this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. In case of any dispute hereunder, the Parties will submit to the exclusive jurisdiction and venue of any court of competent jurisdiction sitting in County of San Diego, California, and will comply with all requirements necessary to give such court jurisdiction over the Parties and the controversy. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to that State's choice of law rules.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Independent Review and Advice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  By signing his name below, the Employee expressly acknowledges that he has read this Agreement, has had the opportunity to ask Employer representatives questions about it, has had the opportunity to consult with an attorney of his choice (at his own expense) before signing it, and understands the contents of this Agreement.  The Employee further agrees that signing this Agreement is a condition of his employment with the Employer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Costs and Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. In the event of any dispute, controversy, or other proceedings (including litigation or arbitration) arising out of or related to this Agreement, the prevailing party shall be entitled to reimbursement of all of its costs, including attorney and expert witness fees and costs.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. All headings and subdivisions of this Agreement are for reference only and shall not affect its interpretation. In the event that any provision of this Agreement should be held unenforceable by a court of competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Remainder of page left intentionally blank</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">IN WITNESS WHEREOF, the Employer and the Employee have executed this Agreement as of</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">the date first set forth above.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">KIORA PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">&#47;s&#47; Brian M. Strem</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Name&#58; Brian M. Strem, PhD</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Title&#58; President &#38; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">&#47;s&#47; Eric J. Daniels</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Eric J. Daniels, MD, MBA</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit-102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7cef12214f454a06afd7f7422595884c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">KIORA PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">THIS EMPLOYMENT AGREEMENT, entered into as of January 10, 2025 (this &#8220;Agreement&#8221;), is made by and between Kiora Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Employer&#8221;), and Melissa Tosca, CPA (the &#8220;Employee&#8221;) (Employer and Employee collectively, the &#8220;Parties&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">WHEREAS, the Employer desires to employ the Employee and the Employee desires to be employed by the Employer, upon and subject to the terms set forth in this Agreement&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NOW, THEREFORE, in consideration of the covenants and the mutual promises contained herein, the Parties hereto hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Freedom to Contract</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  The Employee represents that she is free to enter into this Agreement, that she has not made and will not make any agreements in conflict with this Agreement, and that she will not disclose to the Employer, or use for the Employer&#8217;s benefit, any trade secrets or confidential information that are the property of any other party.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer hereby employs the Employee, and the Employee hereby accepts her employment by the Employer, subject to and upon the terms and conditions set forth herein. The Employee shall be an &#8220;at-will&#8221; employee, subject to the terms and provisions of this Agreement. This means that Employee&#8217;s employment is of no definite duration and will continue only as long as both Parties consider it of mutual benefit. Notwithstanding Section 10.2 or any other provision of this Agreement, Employee or Employer are free to terminate the employment relationship at any time with or without cause and with or without notice. Although Employee&#8217;s job duties, title, compensation and benefits, as well as Employer&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Employee&#8217;s employment may only be changed in a document signed by Employee and Employer&#8217;s Chief Executive Officer.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Effective Date and Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The effective time of this Agreement shall be as of January 1, 2025 (the &#8220;Effective Date&#8221;) and such employment shall continue thereafter in full force and effect until terminated by either Party in accordance with the provisions of this Agreement. The obligations and agreements of the Employee pursuant to Sections 8.7, 10.2, 10.3, 11, 12, 13, and 15.6 hereof shall survive the termination of this Agreement for any reason. The Enterprise Effective Date (the &#8220;Start Date&#8221;) is September 13, 2022.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Title and Duties&#59; Extent of Services</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt">The Employee shall promote the business and affairs of the Employer as Chief Financial Officer. As Chief Financial Officer of the Employer, the Employee shall have such duties and responsibilities as may be assigned to him by the Employer&#8217;s President and Chief Executive Officer and its Board of Directors (the &#8220;Board of Directors&#8221;) from time to time and such other duties and responsibilities as are normal and customary for Chief Financial Officers. The Employee shall report and be responsible to the Chief Executive Officer. The Employee shall devote her best efforts and entire time, attention and energies to the business and affairs of the Employer. Subject to Section 4.2, unless the Employee has received the approval of the Chief Executive Officer, she shall not participate in any other business, engage in other business activities, or render services to any other business or person, as a principal, consultant, employee, or in any other capacity.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt">During her employment, the Employee may serve on the board of directors, board of advisors, or other similar governing or advisory boards of other companies, institutions, or organizations with the prior written consent of the Chief Executive Officer (not to be unreasonably withheld), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that&#58; (i) the Employee does not use proprietary, confidential and&#47;or trade secret information, property, assets or employees of the Employer in engaging in such activities&#59; (ii) any such activities do not pose a conflict of interest or interfere with the Employee&#8217;s duties to the Employer&#59; and (iii) any such activities are not directly or indirectly for or for the benefit of a business engaged in any commercial activity that is competitive with the Employer or otherwise in breach of the Confidentiality Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:9.67pt">&#91;Reserved&#93;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Compliance with Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Employee acknowledges and agrees that compliance with Employer&#8217;s policies, practices, and procedures is a term and condition of her employment under this Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Location of Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. Employee shall work out of Employee&#8217;s home office in San Diego County or shall work at any other location mutually agreed upon by the Employer and the Employee, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that Employee complies with her obligations to travel regularly for business from time to time, consistent with the Employer&#8217;s business needs.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer shall pay the Employee a gross salary at the rate of Twenty Eight Thousand Eighty Three and 33&#47;100 Dollars ($28,083.33) per month (which annualizes to Three Hundred Thirty Seven Thousand Dollars ($337,000.00)), subject to all applicable statutory deductions and withholdings, and payable bi-weekly in arrears or otherwise in accordance with state and local law as well as the Employer&#8217;s normal and customary payroll practices applicable to all of its employees (&#8220;Salary&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  The Employee shall be eligible to receive a performance bonus with respect to each fiscal year of the Employer. Payment of any such performance bonus and the amount, if any, of any such performance bonus shall be entirely at the discretion of the Board of Directors, with an annual target of up to forty percent (40%) of the Employee&#8217;s annual Salary (&#8220;Performance Bonus&#8221;). In determining the amount of any Performance Bonus to be paid to Employee, the Board of Directors shall consider the extent to which the performance criteria established between the Employee and the Board of Directors with respect to such fiscal year has been achieved. Notwithstanding anything express or implied in this Section 8.2 to the contrary, in order to be entitled to receive any performance bonus, the Employee must remain an employee of the Employer on the date that the Employer makes payment of any Performance Bonus.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Medical Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  During the term of this Agreement, the Employee shall be entitled to participate in the health insurance plan offered or generally made available to the Employer&#8217;s employees, under the same terms and conditions as those offered to other, similarly situated employees of the Employer, except as otherwise provided in Section 10.2(d) hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Paid Time Off and Choice Leave</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  During the term of this Agreement, the Employee shall be entitled to paid time off and choice leave, which includes paid sick leave, consistent with the Employer&#8217;s policy concerning paid time off and choice leave and applicable state and local law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. During the term of the Employee&#8217;s employment with the Employer pursuant to this Agreement, the Employee shall be entitled to receive such other retirement, welfare and fringe benefits (&#8220;employee benefits&#8221;) as are provided by the Employer to its senior executives and&#47;or key employees, in each case in accordance with the terms and conditions set forth in the plan, agreement or arrangement representing or evidencing such benefits.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Discretionary Nature of Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employee understands that the Employer may amend, change or cancel or terminate any of its employment policies and &#8220;employee benefits&#8221; at any time as allowed by law or by any applicable plan, agreement or arrangement representing or evidencing such employee benefits.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. All compensation and benefits (including, without limitation, any fringe benefits, bonuses, non-cash compensation, subsidies, severance pay or benefits under Article 8 and Section 10.2 hereof) payable or to be provided to the Employee shall be subject to all applicable withholding taxes, to applicable foreign, federal, state and local deductions, and to any other proper deductions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:9.67pt;text-decoration:underline">Stock Options&#59; Acceleration Upon Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt">The Employee shall be eligible for grants of stock options (the &#8220;Options&#8221;) under the Employer&#8217;s 2024 Equity Incentive Plan, as may be amended from time to time (the &#8220;Plan&#8221;), subject to the discretion of the Board of Directors. The Options shall be incentive stock options to purchase shares of the Employer&#8217;s common stock, $0.01 par value per share (the &#8220;Common Stock&#8221;). The Options, if any, shall be subject to, and governed by, the terms and provisions of the Plan and stock option agreement(s) granted thereunder (&#8220;Stock Option Agreements&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:4.11pt">Upon a Change of Control, all of the Employee&#8217;s then unvested stock options and&#47;or restricted stock awards granted to the Employee prior to such Change of Control under the Plan, including, but not limited to, all stock options previously granted, shall become fully vested and immediately exercisable, notwithstanding any vesting schedule or other provisions to the contrary in the agreements evidencing such options or awards, and the Employer and the Employee hereby agree that such stock option agreements and restricted stock awards are hereby, and will be deemed to be, amended to give effect to this provision. For the purposes hereof, a &#8220;Change of Control&#8221; occurs upon (a) the closing of any merger or consolidation of the Employer with any other unrelated person or entity, or (b) the sale of all or substantially all of the assets of the Employer to another unrelated person or entity, or (c) the sale of more than fifty percent (50%) of the total voting power of the stock of the Employer to an unrelated party, such that, in each case, the transaction has been approved by the Employer&#8217;s stockholders, and in which the stockholders of the Employer immediately prior to such merger, consolidation or sale shall, immediately after such merger, consolidation or sale, own less than fifty percent (50%) of the issued and outstanding capital stock of the person or entity that is the surviving company of any such merger or consolidation, or the acquirer in the case of any such sale of all or substantially all of the assets of the Employer. The provisions of this paragraph shall apply only if the Employee is actively employed by the Employer as a full time employee at the time of a Change of Control.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:3.05pt;text-decoration:underline">Termination Rights of the Parties</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer may terminate the Employee&#8217;s employment at any time by giving notice of termination to the Employee, whereupon, unless otherwise specified by the Employer, the date of termination of the Employee&#8217;s employment shall be the date on which notice of termination is given to the Employee. Upon the death of the Employee or the Employee&#8217;s disability such that she is unable to perform her duties as determined, in good faith, by the Chief Executive Officer, her employment shall terminate immediately upon such occurrence. Subject to Section 13, the date on which the Employee&#8217;s employment terminates hereunder is hereinafter referred to as the &#8220;Termination Date&#8221;.</font></div><div style="padding-left:36pt;text-indent:-4.5pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:3.05pt;text-decoration:underline">Employee&#8217;s Right to Compensation Following Termination&#59; Severance Pay</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If the Employee&#8217;s employment hereunder terminates for any reason whatsoever, the Employer shall pay all of her (or, in the case of death, her estate) accrued but unpaid Salary and Paid Time Off through and including the Termination Date, which amounts shall be paid to the Employee (or her estate) in a lump sum as of such Termination Date, in accordance with applicable law. Subject to the terms and conditions of this Agreement, the Employee shall also be entitled to such other accrued benefits for which she is eligible under the terms and conditions of the Employer&#8217;s employee benefit plans, stock options arrangements, and any applicable law. The accrued compensation and benefits described in this Section 10.2(a) are collectively referred to as the &#8220;Accrued Benefits.&#8221;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If (i) the Employee voluntarily terminates her employment hereunder without Good Reason (as defined in Section 10.2(e) below) or (ii) the Employee&#8217;s employment hereunder terminates by reason of her death or disability or (iii) the Employer terminates the employment of the Employee, at any time, for Cause, then, other than the Accrued Benefits, neither the Employee nor her </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">estate, heirs or other successors shall be entitled to severance pay or other benefits under this Agreement after the Termination Date.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt">If the employment of the Employee is terminated by the Employer for any reason other than for Cause (as defined in Section 10.2(e) below) at any time or if the employment of the Employee is terminated by the Employee for Good Reason then, subject to Sections 10.3 and 13 and subsection (d) hereof, and in addition to the Accrued Benefits, the Employee shall be entitled to&#58; (i) severance pay in the form of a continuation of the periodic payment of her Salary for a period of six (6) months from the Termination Date&#59; and (ii) an amount equal to the product of (A) the maximum performance bonus, pursuant to Section 8.2, that she would have been eligible to receive for the year in which such termination occurs, multiplied by (B) 0.5, which shall be payable no later than the last installment of her severance. The continued Salary payments referred to in the foregoing clause (i) shall be made in accordance with the Employer&#8217;s standard payroll practices and timing as in effect from time to time.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">If (i) the employment of the Employee is terminated by the Employer for any reason other than for Cause, or if the employment of the Employee is terminated by the Employee for Good Reason at any time, and (ii) if the Employee elects under COBRA or an analogous state law continuation coverage under the Employer&#8217;s health and dental plans, then the Employer will subsidize the cost of such coverage and pay the employer portion of such coverage for a period of six (6) months from the Termination Date, under the same terms and conditions then applicable to active employees with identical coverage (&#8220;COBRA Subsidy&#8221;), except that the Employee must pay the employee portion for such coverage by making each monthly co-payment to the Employer, in full, no later than the first five (5) business days of any month during which such COBRA Subsidy applies. If the Employee has elected continuation coverage under COBRA or any analogous state law, then the Employee shall be responsible for all costs for any remainder of the COBRA (or analogous) period. If the Employee has, instead, elected health and dental coverage under a state exchange, then the Employee shall pay the cost of premiums for such coverage directly, subject to reimbursement by the Employer for an amount equal to the COBRA Subsidy, and the Employer shall pay any such reimbursement, in full, no later than thirty (30) days after the eighteen (18) month anniversary of the Employee&#8217;s Termination Date. Notwithstanding anything herein to the contrary, (A) the amount of the COBRA Subsidy shall not exceed the dollar amount provided to similarly situated active employees of the Employer, and (B) to the extent that the Employer&#8217;s payment of such COBRA Subsidy to the Employee is treated as a violation of any applicable non-discrimination laws under the Affordable Care Act, then such COBRA Subsidy shall be unavailable to the Employee under this subsection and her severance under subsection (c) hereof shall be increased by an amount equal to the dollar value of the COBRA Subsidy that would have otherwise been available. Notwithstanding any other provision herein to the contrary, any reimbursement of the COBRA Subsidy shall be paid to the Employee no later than December 31 of the year following the year in which the COBRA expense was incurred.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">For purposes of this Agreement, &#8220;Cause&#8221; shall mean (i) the Employee&#8217;s willful failure to perform her duties (other than any such failure resulting from incapacity due to physical or mental illness or any protected reason under federal, state, or local law), (ii) the Employee&#8217;s willful failure to comply with any valid directive of the Board of Directors, (iii) the Employee&#8217;s engagement in dishonesty, illegal conduct, or misconduct, which is, in each case, materially injurious to the Employer or its affiliates, (iv) the Employee&#8217;s embezzlement, misappropriation, or fraud, whether or not related to the Employee&#8217;s employment with the Employer, (v) the Employee&#8217;s conviction or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude, subject to applicable law, (vi) the Employee&#8217;s material violation of the Employer&#8217;s written policies or codes of conduct, or (vii) the Employee&#8217;s material breach of any material obligation under this Agreement, the Confidentiality Agreement or any other written agreement between the Employee and the Employer. For the purposes of this Agreement, &#8220;Good Reason&#8221; shall mean (i) the failure of the Employer to employ the Employee in her current position such that Employee&#8217;s duties, authority, or responsibilities are materially diminished without the Employee&#8217;s consent&#59; (ii) a material reduction in the Employee&#8217;s aggregate Salary below the amount stipulated in Section 8.1 hereof without the Employee&#8217;s consent (unless such reduction is in connection with a proportional reduction in compensation to all or substantially all of the Employer&#8217;s officers)&#59; or (iii) a material breach by the Employer of this Agreement. The Employee cannot terminate employment for Good Reason unless the Employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">has provided written notice to the Employer of the existence of the circumstances providing grounds for termination for Good Reason and the Employer has had at least thirty (30) calendar days from the date on which such notice is provided to cure such circumstances.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:8.57pt">In the event that the employment of the Employee is terminated by the Employer for any reason other than for Cause or in the event that the Employee voluntarily terminates her employment hereunder for Good Reason, then that portion of the Employee&#8217;s then unvested stock options and&#47;or restricted stock awards granted to the Employee under any Employer stock option plan which would have become vested over the three (3) month period following such termination (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">provided </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">that such period shall be extended to a total of six (6) months if the Employee&#8217;s date of termination occurs on or after the eighteen (18) month anniversary of the Start Date or at any time following a Change of Control) had the Employee continued as an employee of Employer throughout such applicable period, shall, instead, become fully vested and immediately exercisable on the Termination Date, notwithstanding any vesting schedule or other provisions to the contrary in the agreements evidencing such options or awards, and the Employer and the Employee hereby agree that such stock option agreements and restricted stock awards are hereby, and will be deemed to be, amended to give effect to this provision.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">The Employee hereby acknowledges and agrees that (i) she shall not be entitled to receive any compensation or benefits from the Employer with respect to any period of time after the Termination Date except to the extent any Accrued Benefits and as otherwise expressly provided in this Section 10.2.&#59; and (ii) the Employer may set off any amounts the Employee owes the Employer against any amounts the Employer owes the Employee at the date of termination except for amounts the Employer is not entitled by law to set off. Employee agrees to execute any agreement outlining and agreeing to such an offset.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10.3  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">Employee Release</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  Any obligation of the Employer to provide the Employee severance payments or other benefits under this Agreement is expressly conditioned upon the Employee reviewing and signing (and not revoking during any applicable revocation period) a general release of claims in a form reasonably satisfactory to the Employer and to the Employee (the &#8220;Release&#8221;). The Employer shall provide the Employee with the Release promptly after the date on which the Employee gives or receives, as the case may be, notice of termination of the Employee&#8217;s employment. Payment of all severance payment or other benefits to which the Employee may be entitled after the Termination Date, other than the Accrued Benefits, shall commence after the effective date of the Release, as set forth in the Release. To the extent that the Release&#8217;s effective date occurs after severance payments or other benefits may become due under Section 10.2 hereof, the payments that have accumulated between the Termination Date and before the Release&#8217;s effective date will be paid in a lump sum in the first payment made after the Release&#8217;s effective date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Proprietary Information, Inventions and Non-Solicitation Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employee hereby acknowledges that she has entered into the Employer&#8217;s standard form of Proprietary Information, Inventions and Non-Solicitation Agreement (the &#8220;Confidentiality Agreement&#8221;), which is incorporated herein as if reproduced in its entirety. By accepting this Agreement, the Employee hereby ratifies and accepts the terms of the Employee Proprietary Information, Inventions and Non-Solicitation Agreement and agrees to abide by its terms. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">12. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Unique Nature of Agreement&#59; Specific Enforcement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer and the Employee agree and acknowledge that the rights and obligations set forth with this Agreement are of a unique and special nature and that the Employer is, therefore, without an adequate legal remedy in the event of the Employee&#8217;s violation of any of the covenants set forth in this Agreement. The Employer and the Employee agree, therefore, that each of the covenants made by the Employee under this Agreement shall be specifically enforceable in equity, without the need to post a bond or provide other security, in addition to all other rights and remedies, at law or in equity or otherwise (including termination of employment), that may be available to the Employer.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Section 409A of the Code.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Anything in this Agreement to the contrary notwithstanding, if at the time of the Employee&#8217;s separation from service within the meaning of Section 409A of the United States Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), the Employer determines that the Employee is a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then the payment of any deferred compensation hereunder shall not commence until the date that is the earlier of&#58; (A) six (6) months and one (1) calendar day after the Employee&#8217;s separation from service&#59; and (B) her death. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Any installment payments of severance or other deferred compensation under this Agreement shall be deemed a series of separate payments for purposes of section 409A of the Code.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">To the extent necessary to comply with Section 409A of the Code, if the period for considering and executing the Release under this Agreement spans two (2) calendar years, then the severance or payment will not be made or commence until the later calendar year.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Notwithstanding anything herein to the contrary, no event shall constitute a &#8220;termination of employment&#8221; in this Agreement, unless such event is also a &#8220;separation from service,&#8221; as that term is defined for purposes of Section 409A of the Code and Treasury Regulations &#167;1.409A-3(a)(1) and 1.409A-1(h), and any references hereunder to &#8220;termination of employment&#8221; shall have the same meaning as &#8220;separation from service,&#8221; as so defined.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">The Parties intend that this Agreement will be administered in accordance with Section 409A of the Code such that no tax is triggered thereunder. To the extent that any provision of this Agreement is ambiguous as to such compliance with Section 409A of the Code, the provision shall be read in such a manner that all payments hereunder so comply with Section 409A of the Code. The Parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional tax cost to either party.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">13.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">The Employer makes no representation or warranty as to the compliance of this Agreement with Code Section 409A, and, other than its tax withholding obligation, the Employer shall have no liability to the Employee or any other person if any provisions of this Agreement is determined to constitute deferred compensation taxable under Section 409A of the Code. However, the Parties agree to reasonably cooperate and work together to adopt amendments to this Agreement to the extent necessary to comply with Section 409A of the Code with the intent to avoid liability under Code Section 409A.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Treatment of Parachute Payments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt">Notwithstanding any other provision of this Agreement to the contrary, if any of the payments or benefits provided or to be provided by the Employer or its affiliates to the Employee or for the Employee&#8217;s benefit pursuant to the terms of this Agreement or otherwise (&#8220;Covered Payments&#8221;) constitute parachute payments (&#8220;Parachute Payments&#8221;) within the meaning of Section 280G of the Code and would, but for this Section 14, be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the &#8220;Excise Tax&#8221;), then, subject to Section 14.3, the Covered Payments shall be either&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax (that amount, the &#8220;Reduced Amount&#8221;)&#59; or</font></div><div style="padding-left:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">payable in full if the Employee&#8217;s receipt on an after-tax basis of the full amount of payments and benefits (after taking into account the applicable federal, state, local and foreign income, employment and excise taxes (including the Excise Tax)) would result in the Employee receiving an amount at least five percent (5%) greater than the Reduced Amount.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.2  Any such reduction pursuant to Section 14.1 shall be made in accordance with Section 409A of the Code and the following&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">the Covered Payments which do not constitute nonqualified deferred compensation subject to Section 409A of the Code shall be reduced first&#59; and</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:5.78pt">all other Covered Payments shall then be reduced as follows&#58; (i) cash payments shall be reduced before non-cash payments&#59; and (ii) payments to be made on a later payment date shall be reduced before payments to be made on an earlier payment date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">14.3  Any determination required under this Section 14, including whether any payments or benefits are Parachute Payments, shall be made by the Employer in its reasonable discretion. The Employee shall provide the Employer with such information and documents as the Employer may reasonably request in order to make a determination under this Section 14. The Employer&#8217;s determination shall be final and binding on the Employee.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:4.11pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Equal Employment Opportunity</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. The Employer is an equal opportunity employer and is committed to providing a work environment that is free of discrimination. In keeping with this commitment, we maintain a strict policy prohibiting unlawful discrimination based on race (including traits typically associated with race such as certain hairstyles), color, creed, religion (includes religious dress and grooming practices), sex, gender (including pregnancy, childbirth, breastfeeding and&#47;or related medical conditions), reproductive health decisions, gender identity and&#47;or gender expression (including, without limitation, transgender, transsexualism, non-binary, gender non-conforming), marital status, sexual orientation, age (40 and over), national origin (including language use and possession of a driver&#8217;s license issued to persons unable to prove their presence in the United States as authorized under federal law), citizenship, immigration status, military or veteran status, physical handicap, disability (physical and mental, including HIV and AIDS), medical condition, genetic characteristic or information, ancestry, the use of cannabis off the job and away from the workplace, or based on any other consideration made unlawful by federal, state, or local laws. This commitment applies to all personnel decisions and to all persons involved  in  our  operations,  including  volunteers  and  interns.  The  Employer  prohibits discrimination not just on the basis of individual protected characteristics, but also on the basis of the intersectionality (combination) of two or more protected traits. Employee is expressly prohibited from discriminating against, retaliating against, or harassing any employee, customer, contractor, or intern of the Employer. Employee must treat all individuals working for or on behalf of the Employer respectfully and appropriately.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement, the Confidentiality Agreement, and the Stock Option Agreements shall represent the entire agreement of the Parties with respect to the arrangements contemplated hereby. No prior agreement, whether written or oral, shall be construed to change, amend, alter, repeal or invalidate this Agreement. This Agreement may be amended only by a written instrument executed in one or more counterparts by the Parties.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. No consent to or waiver of any breach or default in the performance of any obligations hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of any of the same or any other obligations hereunder. Failure on the part of either Party to complain of any act or failure </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to act of the other Party or to declare the other Party in default, irrespective of the duration of such failure, shall not constitute a waiver of rights hereunder and no waiver hereunder shall be effective unless it is in writing, executed by the Party waiving the breach or default hereunder.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their respective successors and assigns and, in the case of the Employee, her heirs. This Agreement may be assigned by the Employer to any Affiliate of the Employer and to a successor of its business (whether by purchase or otherwise). &#8220;Affiliate of the Employer&#8221; means any person which, directly or indirectly, controls or is controlled by, or is under common control with, the Employer and, for the purposes of this definition, &#8220;control&#8221; (including the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of another, whether through the ownership of voting securities, the holding of office in another, by contract, or otherwise. The Employee may not assign or transfer any or all of her rights or obligations under this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. In case of any dispute hereunder, the Parties will submit to the exclusive jurisdiction and venue of any court of competent jurisdiction sitting in County of San Diego, California, and will comply with all requirements necessary to give such court jurisdiction over the Parties and the controversy. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to that State's choice of law rules.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Independent Review and Advice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">.  By signing her name below, the Employee expressly acknowledges that she has read this Agreement, has had the opportunity to ask Employer representatives questions about it, has had the opportunity to consult with an attorney of her choice (at her own expense) before signing it, and understands the contents of this Agreement.  The Employee further agrees that signing this Agreement is a condition of her employment with the Employer.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.7</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Costs and Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. In the event of any dispute, controversy, or other proceedings (including litigation or arbitration) arising out of or related to this Agreement, the prevailing party shall be entitled to reimbursement of all of its costs, including attorney and expert witness fees and costs.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">15.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:34.55pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. All headings and subdivisions of this Agreement are for reference only and shall not affect its interpretation. In the event that any provision of this Agreement should be held unenforceable by a court of competent jurisdiction, such court is hereby authorized to amend such provision so as to be enforceable to the fullest extent permitted by law, and all remaining provisions shall continue in full force without being impaired or invalidated in any way.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Remainder of page left intentionally blank</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">IN WITNESS WHEREOF, the Employer and the Employee have executed this Agreement as of</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">the date first set forth above.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">KIORA PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">By&#58; &#47;s&#47; Brian M. Strem</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Name&#58; Brian M. Strem, PhD</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Title&#58; President &#38; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline">&#47;s&#47; Melissa Tosca</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Melissa Tosca, CPA</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>kprx-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b95297b3-4120-4902-a1ed-c91851d8eedf,g:f30a331b-4605-4c84-a3e8-7fcd5123b499-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20250110">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>kprx-20250110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b95297b3-4120-4902-a1ed-c91851d8eedf,g:f30a331b-4605-4c84-a3e8-7fcd5123b499-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7b82f84f-5caf-4e27-857c-90f80668720b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d2fa3ec6-9ec8-4891-aeb9-b7666fad3b43_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_12744562-d946-444c-8c85-7cbd3431ec3a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d43285f5-7cc0-4fbd-a15b-c8404c48fa6f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_54a05eda-a6a3-4f6c-b1d0-80245387d070_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_411e296d-1512-4661-847c-a60d22bcb355_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_120e9732-45eb-4220-90ba-9e9abf3d2ff1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_06fc71ef-1797-48ea-ad44-da001da78e85_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_75ebd10e-3c85-4958-a814-e3102dfe5208_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0d184208-0266-4496-b992-a4f35bb5c660_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3153404c-1baf-446a-b3ea-d423620fe218_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_ee36535b-f81c-4e90-bb62-f99330d50e75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ab929a93-2d05-4f4b-b0ca-4b986d92ced5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1b9c3673-b5c5-48f0-a320-e7dd98e3ebda_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a6d71419-181e-476b-9e5a-41963a49b938_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a0514a2e-4ee4-4fe0-897b-ab30ad76dcc5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_aa486774-bb05-4355-abb4-11295282670d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a107958b-4b4b-4c1b-898a-c6317d1be0ce_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_34bcf59d-12b5-49ef-a1b0-9f7b8d9deda0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0fcab935-93ac-4798-9f7a-bf938fe45805_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_33bfaff5-f86f-4234-a706-d2b5b627a292_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f798739d-2862-41d3-a226-20d4ed186c20_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f6104e2a-ae3b-4ace-b09c-4d0a2a70fcfa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>kprx-20250110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:b95297b3-4120-4902-a1ed-c91851d8eedf,g:f30a331b-4605-4c84-a3e8-7fcd5123b499-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20250110.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dab32d77-5606-458b-9e37-bd67da812c3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_DocumentType_dab32d77-5606-458b-9e37-bd67da812c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e3da65c5-2aa8-4e3e-81dd-f8a7088f558e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_DocumentPeriodEndDate_e3da65c5-2aa8-4e3e-81dd-f8a7088f558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2af8ea64-6633-41d5-806a-f5a239c5f373" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityRegistrantName_2af8ea64-6633-41d5-806a-f5a239c5f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0e5df51e-c082-4aa3-bdca-d662d3357f6d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0e5df51e-c082-4aa3-bdca-d662d3357f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9bc1a5cb-51ac-43d5-ae60-a563a74d74d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityTaxIdentificationNumber_9bc1a5cb-51ac-43d5-ae60-a563a74d74d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a0b48af4-f6ad-4af4-b32a-02ddade0ef86" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityFileNumber_a0b48af4-f6ad-4af4-b32a-02ddade0ef86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_60d82c1c-cd7d-4533-a28b-6c0ddeac84c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityAddressAddressLine1_60d82c1c-cd7d-4533-a28b-6c0ddeac84c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4cbc355b-d2da-4329-a4cc-0566d42e4ce4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityAddressAddressLine2_4cbc355b-d2da-4329-a4cc-0566d42e4ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_66bc061c-b890-4a65-ac14-3d7fd940e6a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityAddressCityOrTown_66bc061c-b890-4a65-ac14-3d7fd940e6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_612e09fc-982e-41fe-8b75-36d92aceaae9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityAddressStateOrProvince_612e09fc-982e-41fe-8b75-36d92aceaae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3bdc8895-3fb4-4ef1-aaeb-8cc5373b2db6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityAddressPostalZipCode_3bdc8895-3fb4-4ef1-aaeb-8cc5373b2db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a5508b78-d8c0-4ddd-afa4-069aae8889d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_CityAreaCode_a5508b78-d8c0-4ddd-afa4-069aae8889d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9bf3bba1-1afa-4fd2-a8e1-e49be678dd2a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_LocalPhoneNumber_9bf3bba1-1afa-4fd2-a8e1-e49be678dd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e65c9956-ab45-4b6f-b200-ff77bbafbf84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_WrittenCommunications_e65c9956-ab45-4b6f-b200-ff77bbafbf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b3dac2e9-3f5b-4813-b3ad-5df43dd6424a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_SolicitingMaterial_b3dac2e9-3f5b-4813-b3ad-5df43dd6424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f1c69034-4926-4dc0-9506-daac89f106ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_PreCommencementTenderOffer_f1c69034-4926-4dc0-9506-daac89f106ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_944ca7b8-d6b6-4108-9572-e515a951094d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_944ca7b8-d6b6-4108-9572-e515a951094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_81391c3a-b018-4e67-bdbe-3b5594fb65e6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_Security12bTitle_81391c3a-b018-4e67-bdbe-3b5594fb65e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d3385849-31fe-4045-93b8-1b289b511989" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_TradingSymbol_d3385849-31fe-4045-93b8-1b289b511989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fad22589-1a1c-4ac9-ade2-fa460eaa94eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_SecurityExchangeName_fad22589-1a1c-4ac9-ade2-fa460eaa94eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1a868127-e64c-4224-a0f9-ddb627370c6c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityEmergingGrowthCompany_1a868127-e64c-4224-a0f9-ddb627370c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b3064ee6-2bdf-4262-8dc4-ffe5b7111320" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_EntityCentralIndexKey_b3064ee6-2bdf-4262-8dc4-ffe5b7111320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0deb4b94-ef42-4d4d-9f46-b0cd6aefcd3a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_702e62c8-417a-4e25-abc2-2bd52ce56d6e" xlink:to="loc_dei_AmendmentFlag_0deb4b94-ef42-4d4d-9f46-b0cd6aefcd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46362998560736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI+9]QW,^+DS%:FWLA<:@E[ 5GW'S.9EH:#4*E5#$7*9"2:+YLN_XWNT=;=N
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( -J*+UK-0">7[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( -J*+UJ97)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ VHHO
M6O%"D41:!   &A$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( -J*+UJ?H!OPL0(  .(,   -
M      "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ VHHO6I>*NQS
M    $P(   L              ( !>0\  %]R96QS+RYR96QS4$L! A0#%
M  @ VHHO6JK$(A8S 0  (@(   \              ( !8A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( -J*+UHD'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -J*+UIED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20250110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="kprx-20250110.htm">kprx-20250110.htm</File>
    <File>kprx-20250110.xsd</File>
    <File>kprx-20250110_lab.xml</File>
    <File>kprx-20250110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kprx-20250110.htm": {
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "kprx-20250110.htm"
     ]
    },
    "schema": {
     "local": [
      "kprx-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20250110_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eyegatepharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20250110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001372514-25-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-25-000003-xbrl.zip
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M04BI4E81G*FDO_D?2]J#X _>]R=2/P)$,0F>*^.H6<(9X=-5,_D%-@X?P&\
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M]K4,Q'!P,!R\&*(CVJ-:+UF[U<\\->5<@3O:!4R=*]O:F@UH19DSRWW\,BF
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M#TT\D#H.099M JMM]=N-,'7A,/K6RX8?BAL'Q=@2$H4O )(".X"92/)-47Z
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M36B5CC%&K^36E!52.0R^H*>QQ/Y=[31IC.LD'&\.4L.QY9E!\@8B+B>J+G4
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MI6<9VVHR[06Y1'F_%V;Q"Q<5@?" S)VJ:9@//PWRX4W5@!]P4Q$5+L&;=X4
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M3F5MZFA,6;$Q8T/^":!Y/L.YC<7422"E_H#R;LLN[]WRKD<))/08J33(4_Q
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M@OV-'ZFY&!/,M/ "^ZKVK)KIW7%CX.+3 1DZ!0,1Y XN<70Z]B Z.=C&KC(
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MC^Q]=E<1I4TM?M^&DM@>JU3F$IDQ;YG+;(D> W0=F#6WDCG:R,!]J(*ZHU#
M=2,I0W>[_)G'VL4\%H8.G*=EY9:IX>OI51-O^T1(-)F3*IFJ,_"C&_0G[&BH
M)V8UL%C._G48G>[%W;H.,4YJ+G(,R('^TTWDZ&:HN7(PM<GC=>&HN'J.&-$L
M0^G(E\Q0'K*['\[[@5CDTRU;Y$_W3^G:@TN6R C(&OC<7S2S5KD.@\Y;?W/-
M0H=076A)-&'X=% S-%^F#\W$O,J5WYJH;XH0VY@%HG02M9"9R6"0BT9M"$-W
M=&SC0R;FZ[W:7EYI]"<,>^.@1G&O?$;S4^.:S(3I=NH'S]4::ADLP^:&,O8#
M/CNPYV_=I,>#=+(_WH%.E3')W8CD?'(/XUPQQ*6W)[F.#PTEOO4G &:AG4I=
MSY.-\'YF7Z-%T.RG'?[L=_RM_8X/0^7-=B0(=3UTZ)ON>^'$=WAOX08@VL@S
M"$%AG 44]X\&^+H&Q];D\QA4:6U)D4NC15%S'*);W,'K"9M-#!8O-4-ZL,U>
MC>=^I[XBFCS?N=<8P,*5J_>-6*JZE;K#=3.!DF7=(W7O$=>W-R1[S1Z0U3$T
MF.(KX-Q9&6 J*O"BJ8=7_I@3KPQR'!]G %35-@5#/#OZH(BR*01F!%88]F%
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MW!AVG&#JPL/TK9<-/U:W'HZQ(R2J4 !D%=Z:95/)MU7]$;XPXPXUC.WF%5Z
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M0FM!SQI/-EP1RBH&+T%AA"!8G3_B/6"P!N!)D]^S[0? '; -U<+<%=_4A)#
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M ?,$M^1RLP(N67/)=^=^^3 BS]?,TXV[:\TC&FJ@)-' 8)[9DL2>,V/=VJ"
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M6#M\>L\"@&0*UA24BZ&ZR,LLL#A=M'/_3;C,S 8?=,%PL2E<XVRKQCH "O(
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MU[7H'H2DG*V\R \]!*S@)67URKNYOL0+[VP]FYV^P_CVX]4&7?!BZ( I="Z
M*"C1EJH&J0;0#R[NZ#U!WUJB*BXZC->6=L[[!T'K1J$XC.<.YKQBF6?S.#O)
M$YQ&<8C3+(PQB:#$118MYE&Y "BK]_6R2D*2)%&.TP_A'*?%(L4D@04^J8IR
M'L5)GF:9#;J32UDTT!&D6V-RN9,KKU&J7P;!=KOUMXG/11W$81@%MY\WWRW4
M&[$M97<3]"X7K<,G@7'G1(*#W_5B-X'# ]1:E;XAHB-^P;O ]!Q&D9:5*"5H
M/BBXU.)<0$6&5JV\@?T:2$LK"J56O@6C[03PR*V(J$%](1W(GA3PMYG7,X2,
M*K3KN5"(O<B?-DJ95(05NM&]E!M>$&4GY%6*^<..AXT)1S%.(G\G2R_XAQH.
M8A]7@^,=7X,-)J'P:WX?E$"-A.G+Z>5K<'/ YC#-21CCRO*-9;3U/645WQNT
MR12^=-5?0>7F]]E0CB,<95D66*^>1TLFHA"\A;?!02]X#T)1D(\'V@9H!%0K
MSXPU=N/SLQ?@ZTH<Y%F"Z148M\X 4L^Q[7=S:,B%4 ^]#B'U/;2PE^A_[K\E
M^;']:PJT1S9NB-?:CVBY\LZY?I(]9&PW5Y_^L.@VY9[A0KJ@)52443MVH?TB
MA ]/.$:6=1H\Q3Z),D@HO[*U/3^]VI$\0MX@%J0MAO9XWJ&L5VFCT2DX;E@P
M7;']_Z,UM(;];J]GOP%02P,$%     @ VHHO6J%6&GY0"@  %%@  !4   !K
M<')X+3(P,C4P,3$P7VQA8BYX;6S-7&UOV\@1_IY?P:I?6N VVC>^;'#Q(?4E
M15!?8B0.[M"B$/;5)DX2#8J.[7_?)24YI$5*W*5$]XM-2Z-YYAGQX<P.N?[Y
MEX?%//BN\U6:+=].T&LX"?129BI=7K^=?+OZ )+)+V>O7OW\%P#^^,>7B^#7
M3-XM]+((SG/-"ZV"^[2X"8H;'?R>Y7^FWWEP.>>%R?(% &?5Q\ZSV\<\O;XI
M @QQN#7;OIN_$2S$+!8$4(0AH QBP)%60#*4A$@E6BOST_4;0R G! E (Q@"
M*A,*.-$)B(U4(<)$4,8JI_-T^>>;\H?@*QU8>LM5]>?;R4U1W+Z93N_O[U\_
MB'S^.LNOIQA",MU:3S;F#SOV]Z2R1HRQ:?7ND^DJ;3.T;M'TC]\NOLH;O> @
M7:X*OI0EP"I]LZI>O,@D+ZJL'XPKZ+0H_P);,U"^!! &!+U^6*G)V:L@6*<C
MS^;ZBS9!^?O;EX^=D&Q:6DR7^KK\;B]UGF;J:\'SXH(+/;?15]Z*QUO]=K)*
M%[=SO7WM)M>FW>T\SQM>RRA9&26*RBC_V@4V'1#^D>(M=F,]0G 5W4_'BG%?
M3C\=+=PK>X70IP^X!C,XY/4)]7ZIQCIWGZ &AW[ZB(]U6F0%GX]P6OR J84\
M+U^XL$<;F-+1GHMIA;.Y=-="U0^%7BJ]OEHV7 >I>CNQ1S.ET]G[99$6CQ]M
M:<QOL[RZ<-MK5:'/L[MED3^>9TK/8I%@DU #0LD-H!K'( EC"1@T"8RB),90
MS(JG4WRFE^#;UVTT%:03WL2!=]&AWUROLKM<KBN?C:&L^NNPSM81!(T0?@JJ
M(((L#S:!!&4D/T]_4!B>QOG8R9F/GI=,-M#F92N0Y<_99M*5[0^EK2S=BNI*
MR]?7V?>I]60I8UH>@/*@$EA?_].=K_5=ON7 <WD@RQN+J<QL#W1;@$;"39XM
MO,@6F=<9L4ZY#6EBORZE<]OUMM!K.6O/;=N;\_E'>[5X^)=^G"EL; <J(\"T
M3 !-& )<"P9$'$61X<JVI,1-[L\0QA'X!C2H4 ,+ZZKFYWGIJ]\!;+T4VY^H
MASP[R P0Y'./(TNP@]"NZ+H,?67V(9WK3W<+H?,9PC&E882!8C0"E%()$IF$
M()9"$4J0EH2[*>R'\W'$5>(%:T!76=7RT%=1?NR\Q-2'F(>,=AD,4%#-V<CB
MV:6QJYL6&U_)O%/*?F.KJN)]SB_S['MJ YTI2G 2FE(O$@)JA (<A0+(A$(J
M:6)X9-SDTPXTCI0VV+56:XOOJJR.=/55V? D>"G.@[^' />3&R#&#L<C"W,_
MO5V1'K!W%^Q7+>]RZ_C]@[RQ7[+^Q!=Z%E(.0ZTXX!$G5JB1! (I"!*;QI D
ML8(Q["O4-H 3"W0+&6PQ@Q*TORI;<W)8C4.9NJG0D:23]/8Q\9)<J\/1I+:/
M3EUB>^W<I769V^7>8J%M?.4=BH^KU9W.K\KA3O[9&-M&480T9I$"*$08T"A"
M(*&QM*J#"F,A!0G#OC([!'9BR5EX(&OXP3J 8!U!4(707X ',W=8C,?,AYLP
M!Z7"2:9].7I)]J#ST>3;EV9=RKT_,[#%W?RZ2)<:V>4AU"PF5LJA%H!B# &#
M@@.F&1>&*&P,\NIOZR@C-[>;@Z#$#CXO?7O;1IX<&UM?]L.ZVM[$_9O:-F+#
M.]J&UY=I9]N(=?:RK<8#97EN#S_G5]G]<@8C(V.D#4 QBP%-M.UJ%:5 <0B1
MXG&BD]Y%M@-C9$F6P.5RJX3VE&,M/XYB]&,]3(J]"/O+<)?2<!'6?+Z,!'=)
M=0JPQ=1C'9G-4YD6Z?+Z-[LTS5,^G\6V"BH$-2#EC)2R, $\011H@B!61H<8
M)KU7D3ON3[V&? (,MH@."\C=9/18/@ZBZ+AX=&#GMG+L).&W;MQU-]ZJL9-*
M8\W8;36PAEUFJX+/_YW>5C>AH4()M8(!$$?EK0<6 <$8!IP:$@H1RBCJ/9+I
MAAFYDJVQ PON==N^-5&.]<R;_K"2UI>Y?U5K)3:\L#7=ODQM:Z766=[:K=W%
M>9Y]U_D[L2IR+HL>IUG#_G1G5@43_&<+]-_CG$JMP7N=/4U/HYTPK03JYTB[
M@?MI\7N>%H5>EM.&NV6Z?H1V-2,H).5-+8!$^>@5C3@0Q"X]%,4DPM!HC'KW
M/JT()[Y2;S"#)FC_"W1[5@Z+9C!7-_$XTG22T%XJ7E)J]SB:I/82JDMKO^'Q
M)FYXIC6)0MO_ ),@":AF$ @186 8(P2J$.K8;W%?1WG)B=O5?39\XH8'3-R<
MV!]QXK:/^%$F;GB0%+N]OOC$#;=)\K"QNRS+#2/SRYMLN7TLB N&&6<$8%5N
MB3%4  $E!U2P)%(,2ZUZJ_&Y\Q.+L((+*CSGQZ-V\G!8;4/8N8G,@9B3K+H8
M>*EIQ]EH(NJB4==.IXW_TQ8(BZNTF.L9$DR2*"; KN"M9!(# 2<8 ATKQ1)-
MM%"]GRA\[OS$DJDP@LP$"/]-_#W8HKL_9O&4C!XSL@$4W73CRL[K^8KG- 8]
M6_'D;/3G*I[3:'NF8L?&8P%>5K!<\VK,PR,5(XH80 G2@,:1 $R'MM8@%A%.
MF6"D]P*K[OC$HJEN9918C@.O!O<>LP=/1HZCAWYDW 8/+9'[S1WJCL8;.[2$
MWY@ZM+WO+H7MKN>GC7Z_\L)J H:(<FSEH#6U_9>&(&&Q %P0R%4<*2E[]U^M
M""<6Q]->[C5H8%&#$K:_3-KS<E@O@]FZ"<>9J).$]I+QTE*[Q]%$M9=075W[
M#=UE]LXZ4Z7##W-^/>.<)E$<4R!$N;PA86B5)2A "+,0)SB*H>HKKX;G$\OJ
M"2LHP?J+J<G^L(B\.;F)IR<=)\FTANXEE::GT2322J NC78#WUG<%7_XJ*RS
MU&S&>]L) ((Q"Q-AE_QV\4\E$K8")1S(B*!8(:&AU&[SN ZD<69R%CQHHGON
MG>K*5]^YW!&RX#6;<T^ QVSN +D!\[DNSR//Z X0W)W3'?J NVRO<E[^"YVO
MCPN1S6>$"FE"IH!=E95/YF@#.!(0,!.+1#&E%>_],$'#\ZE'#FNL8 W67X1-
M]H=%Y\W)<<;0CXZ3I%I#]Y)0T]-HDFDE4)=(NX%O)?NBK]/R'O"RJ';Y0".Y
M8"0$C' ):,R24A0<",-(8C0-$^AX0ZD),$[=^H'IN/.I-2=]BY0_4Z_:U)>D
M1T5J9S*@$#US.'+]::>S6W8Z[ ;O?*KOW"%$&&Y,"$P2&4 QH8#', +*5B(1
MX9ACACWW/+W@;J>C;',:M,'I9;8VG7Q/TXEV,_T_[&-RV\%TG+U+VP')E?WH
MS-CJ%A/;!>(DPH B10#'.+*)4U0KE$02]^X"ZX['FA*66.ZCP8IZ_XF@*R'/
M0>!>+E[3OWK@@X9^E:/19WWU\-M&?(WW?9N_]PN=7]M>\I]Y=E_<6+G=\N7C
MS$0(4HTYX)H(0+G40$!FNT$%.;;%RDCC^%]>6G'&:06WT,$:.]B N[:$[9GJ
MVQD.YN_5(+I2]V@4]Q(;T"^V^QVY;=Q+;K=[W&_>)='ZMW%AC\Y>;5])U_]$
M]NS5_P!02P,$%     @ VHHO6D(*Y([8!@   C,  !4   !K<')X+3(P,C4P
M,3$P7W!R92YX;6S5F]MNVT@2AN_]%%KM[;;59W8;L0=>3[(PQC,Q$@]FL#="
M'ZHE(A(IM.C8?OLMTG82'[+#-;4P Q@Z4$U6U5\?V=5%^LU/U^O5Y#/D;5E7
MAU.V3Z<3J$(=RVIQ./W]XATQTY^.]O;>_(V0/__YX6SR<QTNUU UDY,,KH$X
MN2J;Y:19PN2/.G\J/[O)^<HUJ<YK0HZZW4[JS4TN%\MFPBE7]\/N?\T'WBIN
M"R^(9)P2:2DGCD$DP3*C6#0 ,?UC<9 $=4(P3Z2FBLA@)'$"#"E2B(IQX:6U
MW4%79?7IH'WQ;@L3#*_:=E\/I\NFV1S,9E=75_O7/J_VZ[R8<4K%['[T]&[X
M]9/Q5Z(;S:RUL^[7+T.WY7,#\;!L]N>O9Q_#$M:.E-6V<55H#6S+@VVW\:P.
MKNE4_TN_)M\=T7XC]\-(NXDP3@3;O][&Z='>9'(K1ZY7\ '2I'W__</I Y-P
M PO,Y&;I\MKMAWH]:T?-3FJD OWM]F]N-G XW9;KS0KNMRTSI,/IITV^)FUB
M*6.TM?KWVQUG7XUO,FR1F"[8,]QPMW]KY86.P'4#583;"._-K.KP8-"JU;?^
MLN?*>5AU6^<1RGEWU&._;;(+S;R@'#0/!ADL')' %7$^<,)]5#R TE$_BKOU
M>XN.=^G80MA?U)]G>&!,"Y?MAU84V0GRQ-RM."_S^_[\N\"Q\^B\X+$HB-)4
M$ZF,)Q9$07S4172&\2#\(+>_M?;0ZV^3>IS#I,X1,EY [LVY')XD^"&Z=R-F
M&Y?Q0"0LRU6\WSOE>KV+7#7U#I2[30NZ.YU@U ERAGAVFY7O!M=%UN!E%;J1
MN\CX.>2RCF^K^#.>)',0T6D5%.'.H10@@!@6(TG&%=28I)091NRS9GLQP,?/
MP,NU?&48WE9-V=Q\@$79*E$UO[DUS+E+!IR61&O13J-1$4.U(TDY+FQ0211B
M$ O/6>V%@A@O"H.5' 4)IUBKY4V=.^$_HOYP4E]63;XYJ2/,*:B8% ,2J.%$
M.B?P A<<B5KS*(0JDHX[ .._.M&+$SEV3G:G\RBPN7#7IQ'E*U-Y6X3^=KGV
MD.?6!^94\$0Q%X@4R+\#38E36KA"1OQ3.P#F.^9[H:+&CLHNM!T%)._*%=SY
M[JB7QB5)DG81 <=/6#\Y0GF,+@*%9/0.N/AJL1<*>NPHO%#!463_.$94?7OW
MANLV8'--H^&!!1)B@4$HG",=Q])9!QHC.%R3![D##)XQW8N'8NP\#-5TI&#P
MN0P^"*4\B3RB+();XF0(A"JMH^0@ _Q_P."]P# _'AC_FZ9C N,$/[[/%_55
M-=?:!ZJ1;6\LQ8N>1E$"DT3$(D4K*6BWBW+BB>%>4-@?!(H7ZCDF)+J"^7T^
MS_7GL@HPUXP#M2D0:SB@. D7W+Y01.AHN0O@'-C=<?'(>K\^%OU!Z!@B[9@0
M.:^WC5O]N]QT"RJ!RR=C++J=O$1I$B/HN"<F!(5+<,^CWT6]^9SM?GB,N,^Y
M(UE?&8[VJG><P75^.Z4H4FQ(- &O>S%&XI*3A&J+_AL,*0XK+[ZUU@^ $3<Y
M7RS=*Z>\O2&V.E_6%7Q9,2?AO6.$H<M$ILB),\ (2.M!%R9&[@:E_;'%?JD?
M<5-SD(2OG/X_<MDT4)W4Z_5E==<ZV<Y!JV"MTAB_5$1ZG8A'RR2EHL# DD]F
MV*G_K-E^((RX:SE<S%>FX6.]*D/9E-7B5RQP<NE6<R^B"QPLSEZX*I*&">*%
MBT3%)$6,6G(Y['+PU&8_#D;<DAPHXRM#<)ZA)1BPL.WNW+8W_?/[A'[,$PO:
M4H%5C.4:YS6<W*RBFD3G@K&)4>V&W?K^ONU^4(RX.;DC6<<%Q^EV>PGYVUBL
ME,$5'DL?[3$61@W&4G "BBEG%:-6#KO[]5<>] -EQ%W+G4K\VA,*A$N<%&\8
M]Q=ELX(Y7O@L"\(13UE[UU^W3W]X(,(K967R6L&P->9CB_UP&'&O<I"$KYS^
MB^S:9QH_WJQ]O9I'(8PR$N? MD$B*59#5B#&S'-CO6+,FF$-J ?F^B5^Q/W(
MEXLWDI/^[758NFH!W4,>R47.E;&X)F*!2!<L<1$XP66QIN"<E3"L='C.:K\G
MIT;<=1PLY2BZC6_7D!>(\K]R?=4L<7+;N.IFSIS1AO&"@)88!N>2.)HLB=%K
M7HB"!AUVT&Y\UG@_,$;?;QPN["CX.$')LEN=8HES_0O<X&*):@F@6Q42!J Y
M,3%(7#&#\@5C3'P]9P>0\<AL/R9&W((<+N8KTW",]6YL:]YW*[>8TPA>>BL)
M),EQ520CL4EJ+'M"U Y2B&)8Y^&!N7[9'W$7\N7B[2SK;V9/Q#O##4=[=S^T
M+^V_3!SM_0=02P$"% ,4    " #:BB]:3[?6^10Q   )$P$ #P
M    @ $     97AH:6)I="TQ,#$N:'1M4$L! A0#%     @ VHHO6NK16:P#
M+@  P_X   \              ( !03$  &5X:&EB:70M,3 R+FAT;5!+ 0(4
M Q0    ( -J*+UJ;M\)/SA,  .*)   1              "  7%?  !K<')X
M+3(P,C4P,3$P+FAT;5!+ 0(4 Q0    ( -J*+UK;%%%*9 (   @'   1
M          "  6YS  !K<')X+3(P,C4P,3$P+GAS9%!+ 0(4 Q0    ( -J*
M+UJA5AI^4 H  !18   5              "  0%V  !K<')X+3(P,C4P,3$P
M7VQA8BYX;6Q02P$"% ,4    " #:BB]:0@KDCM@&   ",P  %0
M    @ &$@   :W!R>"TR,#(U,#$Q,%]P<F4N>&UL4$L%!@     &  8 ?@$
' (^'      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>kprx-20250110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20250110.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
